Skip to main content
Fig. 2 | Experimental Hematology & Oncology

Fig. 2

From: Leukemogenic SHP2 mutations lead to erythropoietin independency of HCD-57 cells: a novel model for preclinical research of SHP2-mutant JMML

Fig. 2

HCD-57 cells expressing mutant SHP2 are effective tools for drug screening and xenografted mouse models. A Drug screening by using HCD-57 expressing mutant SHP2 and parental cells with a library containing 16 kinase inhibitors. B Cell viability of HCD-57 cells expressing mutant SHP2 and parental cells treated with various concentrations of dasatinib and trametinib. C, D Immunoblot of pSHP2 (Tyr542), SHP2, pERK (Tyr202/204), ERK, pAKT (Ser473), and AKT in HCD-57 cells expressing mutant SHP2 and parental cells. E Weights of spleens of immune-deficient mice injected with HCD-57 cells expressing SHP2-D61Y. F, G Flow cytometry analysis of cells from the bone marrow and spleen of mice injected with HCD-57 cells expressing SHP2-D61Y, which are positive for GFP. The error bar denotes the standard deviation

Back to article page